Navigation Links
Mylan Pharmaceuticals President Tony Mauro Elected Chairman of GPhA
Date:2/24/2012

PITTSBURGH, Feb. 24, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that Tony Mauro, president of Mylan North America and the company's Mylan Pharmaceuticals subsidiary, has been elected to serve as chairman of the Generic Pharmaceutical Association's (GPhA) board of directors. GPhA is an association that represents the world's leading generic drug manufacturers and suppliers. Mauro's election to this role further supports Mylan's mission to impact the future through passionate global leadership on the important issues and policies that shape the generic pharmaceuticals industry.

Mauro said: "I would like to thank the GPhA board of directors and membership for this opportunity, and also acknowledge Ralph Neas for his strong leadership of GPhA since joining the organization. I sincerely look forward to serving as chair and continuing to work closely with the board and Ralph during this truly monumental era in our industry. With growing populations, economic recessions and increasing health care costs, the need for widespread access to more affordable medicine has never been so great. The generic pharmaceutical industry, which accounts for 78% of all prescriptions dispensed in the U.S., has played an important role in saving the U.S. health care system and consumers an estimated $931 billion over the past decade."

"Generic drug makers also have stepped forward to assist the Food and Drug Administration (FDA) in addressing the industry-wide challenges, experienced by both brand and generics companies, caused by the globalization of the drug supply chain and the corresponding increase in the FDA's workload. This effort positions GPhA at the forefront of our industry's important issues, and advises policy makers that they should look to us as a key partner when tackling current and future challenges."

Mauro's term as chairman of GPhA will last for one year. Previously, he served two one-year terms as the vice chairman of the association. In his 15 years at Mylan, Mauro has held roles of increasing responsibility across the company's business units, including president of Mylan Pharmaceuticals, chief operating officer for Mylan Pharmaceuticals ULC in Canada, vice president of Strategic Development, North America, and vice president of Sales, North America.

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 150 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information about Mylan, please visit www.mylan.com. For more information about generic drugs, please visit www.ChoosingGenerics.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Mylan Secures an Additional $300 Million of Committed Financing
2. Mylan Reports Adjusted Diluted EPS of $0.53 for the Quarter, an 18% Increase Over Prior Year Quarter; and $2.04 for the Year, a 27% Increase Over Prior Year
3. Mylan and Pfizer Announce Epinephrine Auto-injector Settlement Agreement
4. Mylan to Change Name of Specialty Subsidiary From Dey Pharma to Mylan Specialty
5. Mylan Actively Addressing Shortage of Preservative-Free Methotrexate Injection
6. Mylan CEO Heather Bresch Testifies Before Congress in Support of Generic Drug User Fee Program and Urges Update of Federal Food, Drug and Cosmetic Act of 1938 to Create a Level Playing Field for Manufacturers
7. Mylan Completes Acquisition of Two Limited-Competition Dermatological Products from Valeant
8. Valeant Pharmaceuticals Completes Divestiture of Generic Dermatology Products to Mylan
9. Mylan Receives Tentative FDA Approval for Generic Version of Lipitor®
10. Mylan to Host Investor Day on Feb. 21, 2012, in New York City
11. Mylan Launches Innovative Version of Antiepileptic Drug Levetiracetam
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/10/2017)... 2017  Physical Rehabilitation Network (PRN), acquired the long-standing outpatient ... Colorado . The reputable clinic will continue to be ... with his staff of four clinicians. Lipkin received his doctorate ... over 10 years of experience with a strong background in ... marks the 10th PRN clinic in and around the ...
(Date:8/8/2017)... Second-quarter 2017 revenues of $876 million and ... operations Second-quarter 2017 Branded ... Second-quarter 2017 Sterile Injectables ... Second-quarter 2017 adjusted diluted earnings per ... $0.93 Second-quarter 2017 reported ...
(Date:8/7/2017)... 7, 2017 Zimmer Biomet Holdings, Inc. (NYSE and ... that its Board of Directors has approved the payment of ... of 2017. The cash ... about October 27, 2017 to stockholders of record as of ... of dividends are subject to approval of the Board of ...
Breaking Medicine Technology:
(Date:8/21/2017)... (PRWEB) , ... August 22, 2017 , ... ... but not without risk to health and safety. By learning and implementing best ... eliminated. , In this webinar, attendees will gain a better understanding of ...
(Date:8/21/2017)... Viejo, CA (PRWEB) , ... August 21, 2017 , ... ... Film Studios. Editors can quickly and easily add washed color grades to footage. ... image. The LUT changes every pixel’s color to the corresponding color indicated by the ...
(Date:8/21/2017)... WI (PRWEB) , ... August 21, 2017 , ... ... years, with events taking place all over the country. , Outdoor running increases ... marathon runners are at an increased risk of melanoma, and only half may ...
(Date:8/21/2017)... ... August 21, 2017 , ... PIXACORE , an independent full-service agency ... Top 100 agencies of the year by MM&M. , This is the first time ... important milestone for the agency. PIXACORE’s newfound recognition reflects its steady trajectory of ...
(Date:8/21/2017)... ... August 21, 2017 , ... Project Hero today ... made a multi-million dollar partnership commitment to support Project Hero’s efforts to ... brain injuries (TBI) over the next year. , Optum’s partnership will help ...
Breaking Medicine News(10 mins):